NasdaqGM:VCYTBiotechs
How Investors May Respond To Veracyte (VCYT) Raising 2026 Revenue Guidance After Returning To Profit
In late July 2026, Veracyte raised its full-year 2026 revenue guidance to a range of US$590 million to US$596 million and reported second-quarter revenue of US$150.32 million, with net income of US$25.49 million compared with a small loss a year earlier.
The shift from loss to profit for both the quarter and first half, alongside higher guidance, highlights improving operating leverage and confidence in the business trajectory.
With Veracyte boosting full-year revenue guidance, we’ll now...